Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elisabeth Mellström
Observed name:
Mellström, Elisabeth
Institutions:
Sahlgrenska University Hospital,
Wallenberg Centre for Molecular and Translational Medicine,
University of Gothenburg
Observed institutions:
Sahlgrenska University Hospital,
Region Västra Götaland,
Drottning Silvias barn- och ungdomssjukhus,
Karlstad Central Hospital,
Wallenberg Centre for Molecular and Translational Medicine,
University of Gothenburg
show all 6
ORCID:
0009-0004-2801-1681
Observed ORCID:
0009-0004-2801-1681
OpenAlex ID:
A5106678848
Methylphenidate and Reduced Overweight in Children With ADHD
2018
·
Elisabeth Mellström
, Cecilia Forsman
, et al.
·
Journal of Attention Disorders
·
31
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
·
Cancer Research Communications
·
16
Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma
2024
·
Ida Rahmqvist
, Enya Engström
, et al.
·
Biomarker Research
·
6
PDF
Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile
2025
·
Ida Rahmqvist
, Agnes Dahlstrand Rudin
, et al.
·
npj Precision Oncology
·
3
PDF
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
·
1
Truncating variants reveal functional divergence of the SAMD9 and SAMD9L paralogues
2026
·
Petar Mitev
, Aditi Khurana
, et al.
·
Journal of Human Immunity
PDF
The Effect of Unique Molecular Identifier Family Size Using Tumor-Informed Circulating Tumor DNA Analysis in Childhood Cancers
2026
·
Tobias Österlund
, Daniel Andersson
, et al.
·
Journal of Molecular Diagnostics
PDF
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Data from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 6 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 5 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Table 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024
·
Torben Ek
, Raghda R. Ibrahim
, et al.
Show more works
View as search
Works count:
36
Citation count:
57
H-index:
3
I10-index:
2
Year
Topic
Type